Announcements Trials
Browse Landscape

Phase

Phase 4 4Phase 3 3Phase EARLY_PHASE1 2Phase NA 1Phase 2 1

Status

Completed 7Withdrawn 1Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1Depression 1Anxiety Disorders 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 142Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Ketamine × Clear all
NCT01680172 2016-02-29

Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer

Mayo Clinic

Phase 2 Terminated
5 enrolled 6 charts

Anxiety Disorders, Depression, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡